Personal Genome Diagnostics, Inc. (PGDx), a Baltimore-based provider of advanced cancer genome testing products and services, raised $21.4m in a Series A funding.
The round was led by New Enterprise Associates (NEA) with participation from Windham Venture Partners and Nanjing Kaiyuan Growth Capital Investments. In conjunction with the financing, NEA Partner Justin Klein, MD, JD, will join PGDx’s board of directors, alongside PGDx co-founders Luis A. Diaz and Victor Velculescu. Felix Dawson and Adam Fine of Windham Venture Partners will join the board as observers.
The company intends to use the funds to expand operationd and adoption of its services.
Founded in 2010 by cancer researchers from Johns Hopkins University (JHU) researchers Luis A. Diaz, MD, and Victor Velculescu, MD, PhD, PGDx provides a platform of advanced genomic analyses in the oncology space, including whole genome sequencing, pan-cancer panels, targeted panels and single gene analysis in tissue and liquid biopsies, as well as custom approaches for target discovery and companion diagnostics.
The company’s service offerings for researchers are complemented by the clinical services it provides through its CLIA-certified laboratory.
PGDx currently has 63 employees who occupy an 11,000 square foot historic facility in Baltimore’s harbor neighborhood. This space houses PGDx’s laboratories, bioinformatic and commercial activities.